{"id":"zl-1310","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":{"chemblId":"CHEMBL5908921","moleculeType":null,"molecularWeight":"453.50"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ZL-1310 targets FGFR mutations and fusions that drive oncogenic signaling in various solid tumors. By inhibiting FGFR kinase activity, the drug suppresses downstream proliferation and survival pathways in FGFR-dependent cancers. This selective approach aims to provide efficacy in tumors with FGFR alterations while potentially minimizing off-target effects.","oneSentence":"ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:23.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-positive or FGFR-altered solid tumors"},{"name":"Cholangiocarcinoma with FGFR alterations"}]},"trialDetails":[{"nctId":"NCT07218146","phase":"PHASE3","title":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2025-11-30","conditions":"Small-cell Lung Cancer","enrollment":480},{"nctId":"NCT06885281","phase":"PHASE1, PHASE2","title":"A Study of ZL-1310 in Participants With Selected Solid Tumors","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2025-05-12","conditions":"Solid Tumors","enrollment":112},{"nctId":"NCT06179069","phase":"PHASE1","title":"A Study of ZL-1310 in Subjects With Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2024-01-23","conditions":"SCLC","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ZL-1310","genericName":"ZL-1310","companyName":"Zai Lab (Shanghai) Co., Ltd.","companyId":"zai-lab-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-positive or FGFR-altered solid tumors, Cholangiocarcinoma with FGFR alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}